Related references
Note: Only part of the references are listed.Intermittent Versus Continuous Dosing of MAPK Inhibitors in Treatment of BRAF-Mutated Melanoma
Coralie Reger de Moura et al.
TRANSLATIONAL ONCOLOGY (2020)
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione et al.
EUROPEAN JOURNAL OF CANCER (2018)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
Brigitte Dreno et al.
LANCET ONCOLOGY (2017)
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
Max Schreuer et al.
LANCET ONCOLOGY (2017)
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers
Helena A. Yu et al.
LUNG CANCER (2017)
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Yaohua Xue et al.
NATURE MEDICINE (2017)
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
Rajasekharan Somasundaram et al.
NATURE COMMUNICATIONS (2017)
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
Chunying Song et al.
CANCER DISCOVERY (2017)
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
Sonya C. Tate et al.
BRITISH JOURNAL OF CANCER (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status
Seigo Minami et al.
LUNG CANCER (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
